Relationship between in vitro phospholipidosis assay using HepG2 cells and 2-week toxicity studies in rats

Toxicology Mechanisms and Methods

Volumn 19, Issue 8, 2009, Pages 477-485

  Miyamoto, Saku ^a   Matsumoto, Akemi ^a   Mori, Ikuo ^a   Horinouchi, Akira ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Fluorometry; HepG2; Phospholipidosis; Screening; Toxicity study

Indexed keywords

1,4 BIS(2 CHLOROBENZYLAMINOMETHYL)CYCLOHEXANE; AMIODARONE; AMITRIPTYLINE; AMPICILLIN; CIMETIDINE; FAMOTIDINE; FLUOXETINE; NEW DRUG; PARACETAMOL; PERHEXILINE; PHOSPHOLIPID; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ASSAY; CELL CULTURE; CELL STRAIN HEPG2; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXICITY; DRUG SCREENING; FEMALE; HUMAN; HUMAN CELL; LAMELLAR BODY; LIPIDOSIS; NONHUMAN; PERFORMANCE; PREDICTION; PRIORITY JOURNAL; RAT; TOXICITY TESTING;

AMIODARONE; ANIMAL TESTING ALTERNATIVES; ANIMALS; CYTOPLASMIC VESICLES; ENZYME INHIBITORS; FEMALE; FLUORESCENT DYES; HEP G2 CELLS; HUMANS; LIPIDOSES; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; ORGAN SPECIFICITY; PHOSPHATIDYLETHANOLAMINES; PHOSPHOLIPIDS; RATS; RATS, SPRAGUE-DAWLEY; SPECTROMETRY, FLUORESCENCE; TIME FACTORS; TOXICITY TESTS;

RATTUS;

EID: 70350116688     PISSN: 15376516     EISSN: 15376524     Source Type: Journal    
DOI: 10.1080/15376510903322834     Document Type: Article

References (25)

1. Amacher DE, Martin BA. 1997. Tetracycline-induced steatosis in primary canine hepatocyte cultures. Fundam Appl Toxicol 40:256-263.
2. Anderson N, Borlak J. 2006. Drug-induced phospholipidosis. FEBS Lett 580:5533-5540.
3. Bhandari N, Figueroa DJ, Lawrence JW, Gerhold DL. 2008. Phospholipidosis assay in HepG2 cells and rat or rhesus hepatocytes using phospholipid probe NBD-PE. Assay Drug Dev Technol 6:407-419.
4. Casartelli A, Bonato M, Cristofori P, Crivellente F, Dal Negro G, Masotto I, Mutinelli C, Valko K, Bonfante V. 2003. A cell-based approach for the early assessment of the phospholipidogenic potential in pharmaceutical research and drug development. Cell Biol Toxicol 19:161-176.
5. Fujimura H, Dekura E, Kurabe M, Shimazu N, Koitabashi M, Toriumi W. 2007. Cell-based fluorescence assay for evaluation of new-drugs potential for phospholipidosis in an early stage of drug development. Exp Toxicol Pathol 58:375-382.
6. Gum RJ, Hickman D, Fagerland JA, Heindel MA, Gagne GD, Schmidt JM, Michaelides MR, Davidsen SK, Ulrich RG. 2001. Analysis of two matrix metalloproteinase inhibitors and their metabolites for induction of phospholipidosis in rat and human hepatocytes(1). Biochem Pharmacol 62:1661-1673.
7. Halliwell WH. 1997. Cationic amphiphilic drug-induced phospholipidosis. Toxicol Pathol 25:53-60.
8. Hashizume T, Yoshitomi S, Asahi S, Matsumura S, Chatani F, Oda H. 2009. In vitro micronucleus test in HepG2 transformants expressing a series of human cytochrome P450 isoforms with chemicals requiring metabolic activation. Mutat Res 677:1-7.
9. Hirode M, Ono A, Miyagishima T, Nagao T, Ohno Y, Urushidani T. 2008. Gene expression profiling in rat liver treated with compounds inducing phospholipidosis. Toxicol Appl Pharmacol 229:290-299.
10. Kasahara T, Tomita K, Murano H, Harada T, Tsubakimoto K, Ogihara T, Ohnishi S, Kakinuma C. 2006. Establishment of an in vitro high-throughput screening assay for detecting phospholipidosis-inducing potential. Toxicol Sci 90:133-141.
11. Kodavanti UP, Mehendale HM. 1990. Cationic amphiphilic drugs and phospholipid storage disorder. Pharmacol Rev 42:327-354.
12. Lullmann-Rauch R. 1979. Drug-induced lysosomal storage disorders. Front Biol 48:49-130.
13. McMillian MK, Grant ER, Zhong Z, Parker JB, Li L, Zivin RA, Burczynski ME, Johnson MD. 2001. Nile Red binding to HepG2 cells: an improved assay for in vitro studies of hepatosteatosis. In Vitro Mol Toxicol 14:177-190.
14. Morelli JK, Buehrle M, Pognan F, Barone LR, Fieles W, Ciaccio PJ. 2006. Validation of an in vitro screen for phospholipidosis using a high-content biology platform. Cell Biol Toxicol 22:15-27.
15. Nioi P, Perry BK, Wang EJ, Gu YZ, Snyder RD. 2007. In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies. Toxicol Sci 99:162-173.
16. Nonoyama T, Fukuda R. 2008. Drug-induced phospholipidosis-pathological aspects and its prediction. J Toxicol Pathol 21:9-24.
17. Pappu AS, Yazaki PJ, Hostetler KY. 1985. Inhibition of purified lysosomal phospholipase A1 by beta-adrenoceptor blockers. Biochem Pharmacol 34:521-524.
18. Ploemen JP, Kelder J, Hafmans T, van de Sandt H, van Burgsteden JA, Saleminki PJ, van Esch E. 2004. Use of physicochemical calculation of pKa and CLogP to predict phospholipidosis-inducing potential: a case study with structurally related piperazines. Exp Toxicol Pathol 55:347-355.
19. Reasor MJ, Hastings KL, Ulrich RG. 2006. Drug-induced phospholipidosis: issues and future directions. Expert Opin Drug Saf 5:567-583.
20. Sawada H, Takami K, Asahi S. 2005. A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci 83:282-292.
21. Shaikh NA, Downar E, Butany J. 1987. Amiodarone-an inhibitor of phospholipase activity: a comparative study of the inhibitory effects of amiodarone, chloroquine and chlorpromazine. Mol Cell Biochem 76:163-172.
22. Tomizawa K, Sugano K, Yamada H, Horii I. 2006. Physicochemical and cellbased approach for early screening of phospholipidosis-inducing potential. J Toxicol Sci 31:315-324.
23. Vitovic P, Alakoskela JM, Kinnunen PK. 2008. Assessment of drug-lipid complex formation by a high-throughput Langmuir-balance and correlation to phospholipidosis. J Med Chem 51:1842-1848.
24. Westerink WM, Schoonen WG. 2007. Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. Toxicol In Vitro 21:1581-1591.
25. Xia Z, Ying G, Hansson AL, Karlsson H, Xie Y, Bergstrand A, DePierre JW, Nassberger L. 2000. Antidepressant-induced lipidosis with special reference to tricyclic compounds. Prog Neurobiol 60:501-512.